Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can ozempic and mounjaro turn back your biological clock?

NCT ID NCT07293325

Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will give 66 adults with obesity either semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), or metformin for 24 weeks. Researchers will use a DNA test called iWatchAge to see if these drugs can reverse or slow the genetic signs of aging. The goal is to find out if treating obesity can also help people age more slowly at a cellular level.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide, tirzepatide, or metformin
What this could lead to
If it works, this could point toward a way to slow biological aging in people with obesity, potentially reducing age-related health risks.
What could go wrong
This is a small, early-stage study with only 66 people. It measures a biomarker (epigenetic age), not actual health outcomes, so results may not translate to real-world benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 66 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged 18 to 75 years. 2. Diagnosed with simple obesity, defined as BMI ≥ 30 kg/m². 3. Have not used any anti-obesity medications (including GLP-1 RAs, tirzepatide, metformin for weight loss, etc.) within the past 3 months. 4. Able and willing to comply with study procedures and complete follow-up assessments. 5. Provide written informed consent. Exclusion Criteria: 1. Presence of secondary obesity (e.g., endocrine disorders such as Cushing's syndrome or hypothyroidism). 2. Use of anti-obesity medications or participation in another weight-loss program within the past 3 months. 3. Diagnosed type 1 or type 2 diabetes mellitus requiring hypoglycemic drug therapy. 4. History of pancreatitis, severe gastrointestinal disease, or bariatric surgery. 5. Severe cardiovascular, hepatic, renal, or psychiatric disease that may affect participation. 6. Pregnant or breastfeeding women, or women planning pregnancy during the study period. 7. Current participation in any other clinical trial. 8. Any condition that, in the investigator's judgment, makes the participant unsuitable for the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adults with simple obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adults with simple obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Second Affiliated Hospital, Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, China